The total return over the past 12 months is +37.62% vs. +19.98% for the S&P 500. So far it's up +20.46% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +37.62% | +15.81% | +22.48% | +19.09% | +18.17% | +14.52% |
| Total Return CAGR | +37.62% | +15.81% | +22.48% | +19.09% | +18.17% | +14.52% |
| Revenue CAGR | +10.56% | +9.92% | +13.57% | +23.28% | +28.98% | +24.08% |
| Net Income CAGR | +21.10% | +9.39% | +17.21% | N/A | N/A | N/A |
| EPS CAGR | +22.49% | +6.03% | +8.17% | N/A | N/A | N/A |
| Free Cash Flow CAGR | +8.47% | (0.71%) | +16.39% | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +11.61% | (0.74%) | +15.15% | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Vertex Pharmaceuticals Incorporated (VRTX)
| Year | Start price | End price | VRTX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $453.36 | $546.12 | +20.46% | +13.55% | +6.91% |
| 2025 | $402.70 | $453.36 | +12.58% | +17.72% | (5.14%) |
| 2024 | $406.89 | $402.70 | (1.03%) | +24.89% | (25.92%) |
| 2023 | $288.78 | $406.89 | +40.90% | +26.19% | +14.71% |
| 2022 | $219.60 | $288.78 | +31.50% | (18.17%) | +49.67% |
| 2021 | $236.34 | $219.60 | (7.08%) | +28.74% | (35.82%) |
| 2020 | $218.95 | $236.34 | +7.94% | +18.37% | (10.43%) |
| 2019 | $165.71 | $218.95 | +32.13% | +31.22% | +0.91% |
| 2018 | $149.86 | $165.71 | +10.58% | (4.56%) | +15.14% |
| 2017 | $73.67 | $149.86 | +103.42% | +21.70% | +81.72% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
